AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10710838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) intervention, n = 47
Number of subjects: 73
Study 10710838 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC), n = 26
Number of subjects: 73
Study 9378150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and cyclophosphamide plus doxorubicin (40 mg/m2)
Number of subjects: 23
Study 9378150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and cyclophosphamide plus doxorubicin (50 mg/m2)
Number of subjects: 23
Study 9378150 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and cyclophosphamide (control)
Number of subjects: 23
Study 8225214 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin plus terlipressin
Number of subjects: 51
Study 8225214 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin alone
Number of subjects: 51
Study 3877279 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 3 mg/kg/h
Number of subjects: 60
Study 3877279 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 6 mg/kg/h
Number of subjects: 60
Study 3877279 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 9 mg/kg/h
Number of subjects: 60
Study 3877279 — intervention group
Group type: EXPERIMENTAL
Intervention: All infusion rates (3, 6, 9 mg/kg/h)
Number of subjects: 60
Study 29654415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day)
Number of subjects: 668
Study 29654415 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole (2.5 mg/day)
Number of subjects: 668
Study 26843523 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DPDT)
Number of subjects: 22
Study 26843523 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial white light photodynamic therapy (AWLPDT)
Number of subjects: 22
Study 26843523 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 22
Study 24709267 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation during the intensive phase of TB treatment
Number of subjects: 100
Study 24709267 — intervention group
Group type: COMPARATOR
Intervention: No nutritional supplementation (control group)
Number of subjects: 100
Study 22672732 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory training
Number of subjects: 40
Study 21034706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser plus methylaminolevulinate
Number of subjects: 0
Study 21034706 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser alone
Number of subjects: 0
Study 18590344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 0.5 or 1.0 mg/kg/day (neonates), or 1.0 or 2.0 mg/kg/day (infants) for 5 days
Number of subjects: 48
Study 18590344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 48
Study 16083023 — intervention group
Group type: EXPERIMENTAL
Intervention: Variations in blood flow and dialysate flow
Number of subjects: 48
Study 12437253 — intervention group
Group type: EXPERIMENTAL
Intervention: G-100 (<= 100 mL/d, n = 44)
Number of subjects: 139
Study 12437253 — intervention group
Group type: EXPERIMENTAL
Intervention: G-150 (<= 150 mL/d, n = 58)
Number of subjects: 139
Study 12437253 — intervention group
Group type: EXPERIMENTAL
Intervention: G-200 (<= 200 mL/d, n = 37)
Number of subjects: 139
Study 12437253 — intervention group
Group type: EXPERIMENTAL
Intervention: G-val (prospective validation group, n = 91)
Number of subjects: 139
Study 10344212 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (F)
Number of subjects: 0
Study 10344212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of finasteride plus terazosin (C)
Number of subjects: 0
Study 10344212 — intervention group
Group type: COMPARATOR
Intervention: Terazosin (T)
Number of subjects: 0
Study 10344212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study 7531900 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/d) for 12 months
Number of subjects: 23
Study 1682247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg body weight)
Number of subjects: 50
Study 1682247 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (0.1 mg/kg body weight)
Number of subjects: 50
Study 1682247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Vecuronium and Pancuronium
Number of subjects: 50
Study 7159500 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar (15.6 g/day) + Bezafibrate (600 mg/day)
Number of subjects: 12
Study 7159500 — intervention group
Group type: COMPARATOR
Intervention: Bezafibrate (600 mg/day) alone
Number of subjects: 12
Study 30536182 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M) 2000 mg/day plus NPLD 60 mg/m2 + cyclophosphamide 600 mg/m2 × 8 cycles Q21 days (arm A)
Number of subjects: 122
Study 30536182 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (NPLD/C) (arm B)
Number of subjects: 122
Study 30536182 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M) in patients with HOMA index < 2.5
Number of subjects: 122
Study 30536182 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone in patients with HOMA index ≥ 2.5
Number of subjects: 122
Study 30536182 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M) plus chemotherapy (arm A)
Number of subjects: 122
Study 30536182 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (arm B)
Number of subjects: 122
Study 30536182 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M) induced diarrhea (G2)
Number of subjects: 122
Study 27907817 — intervention group
Group type: EXPERIMENTAL
Intervention: Featback (fully automated Internet-based intervention)
Number of subjects: 273
Study 27907817 — intervention group
Group type: EXPERIMENTAL
Intervention: Featback with low‐intensity (weekly) therapist support
Number of subjects: 273
Study 27907817 — intervention group
Group type: EXPERIMENTAL
Intervention: Featback with high‐intensity (three times a week) therapist support
Number of subjects: 273
Study 27907817 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 273
Study 26086190 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 66
Study 26086190 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 66
Study 24848974 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g/d Soluble maize fibre (SCF)
Number of subjects: 24
Study 24848974 — intervention group
Group type: COMPARATOR
Intervention: 0 g/d Soluble maize fibre (Control treatment)
Number of subjects: 24
Study 22579053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention with physical activity (n=45)
Number of subjects: 90
Study 22579053 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention without physical activity (n=45)
Number of subjects: 90
Study 18394931 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide treatment in Type 2 diabetic patients
Number of subjects: 14
Study 18394931 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no gliclazide treatment)
Number of subjects: 14
Study 17868472 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus (Rapamune)
Number of subjects: 0
Study 15817859 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium as selenomethionine (37 mug Se/d)
Number of subjects: 120
Study 15817859 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium as selenite (66 mug Se/d)
Number of subjects: 120
Study 15817859 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium as selenomethionine and selenite (highest doses)
Number of subjects: 120
Study 15817859 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium as selenomethionine
Number of subjects: 120
Study 15817859 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended dietary allowance of selenium
Number of subjects: 120
Study 15817859 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium as selenite
Number of subjects: 120
Study 12219859 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtle stereotype activation
Number of subjects: 0
Study 12219859 — intervention group
Group type: EXPERIMENTAL
Intervention: Blatant stereotype activation
Number of subjects: 0
Study 10597397 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid preceded by pantoprazole, 40 mg (P-PCM)
Number of subjects: 107
Study 10597397 — intervention group
Group type: COMPARATOR
Intervention: 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid followed by pantoprazole, 40 mg (PCM-P)
Number of subjects: 107
Study 7489182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexipafant 60 mg intravenously for 3 days
Number of subjects: 83
Study 7489182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 7489182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexipafant
Number of subjects: 83
Study 2201157 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2‐interferon administered until day 7 of jaundice
Number of subjects: 90
Study 2201157 — intervention group
Group type: COMPARATOR
Intervention: common therapy (control group)
Number of subjects: 90
Study 2201157 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2‐interferon administered after day 6 of jaundice
Number of subjects: 90
Study 7362427 — intervention group
Group type: EXPERIMENTAL
Intervention: Community care
Number of subjects: 0
Study 7362427 — intervention group
Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 0
Study 31802405 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii fit game training (40-min sessions, 'Soccer Heading' for first 4 weeks, 'Table Tilt' for last 4 weeks)
Number of subjects: 64
Study 31802405 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 64
Study 31802405 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii fit game training
Number of subjects: 64
Study 31526525 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation (LKM)
Number of subjects: 125
Study 31526525 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness meditation (MM)
Number of subjects: 125
Study 28125979 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 40
Study 28125979 — intervention group
Group type: COMPARATOR
Intervention: ETT
Number of subjects: 40
Study 26061039 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO)
Number of subjects: 33
Study 26061039 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol-Enriched Virgin Olive Oil (FVOO)
Number of subjects: 33
Study 26061039 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol-Enriched Virgin Olive Oil with Thyme (FVOOT)
Number of subjects: 33
Study 23134234 — intervention group
Group type: COMPARATOR
Intervention: CHO trial (8% carbohydrate beverage)
Number of subjects: 9
Study 23134234 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-P trial (6% carbohydrate plus 2% whey protein beverage)
Number of subjects: 9
Study 21884533 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U/kg C1‐INH concentrate (Berinert®)
Number of subjects: 57
Study 19706737 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 224
Study 27936526 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% diclofenac + 3% menthol gel (administered via tube or roll-on device, 4 g applied 4 times daily)
Number of subjects: 18
Study 27936526 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% diclofenac sodium gel (Voltaren Gel, 4 g applied 4 times daily)
Number of subjects: 18
Study 27936526 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac sodium tablets (50 mg, 3 times daily)
Number of subjects: 18
Study 27936526 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% diclofenac + 3% menthol gel
Number of subjects: 18
Study 27936526 — intervention group
Group type: COMPARATOR
Intervention: Voltaren Gel
Number of subjects: 18
Study 27936526 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac
Number of subjects: 18
Study 14516806 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated test using Landolt rings
Number of subjects: 206
Study 14516806 — intervention group
Group type: COMPARATOR
Intervention: ETDRS chart testing
Number of subjects: 206
Study 14516806 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated test
Number of subjects: 206
Study 14516806 — intervention group
Group type: COMPARATOR
Intervention: ETDRS chart
Number of subjects: 206
Study 10838532 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, doxorubicin, cyclophosphamide, and dactinomycin
Number of subjects: 393
Study 10838532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide and etoposide
Number of subjects: 393
Study 10838532 — intervention group
Group type: COMPARATOR
Intervention: Control group (vincristine, doxorubicin, cyclophosphamide, and dactinomycin)
Number of subjects: 393
Study 10838532 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgical resection
Number of subjects: 393
Study 10838532 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed resection
Number of subjects: 393
Study 10838532 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgical resection vs resection after initial chemotherapy
Number of subjects: 393
Study 9099325 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 59
Study 9099325 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 59
Study 8471405 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (25 to 200 mg)
Number of subjects: 0
Study 8471405 — intervention group
Group type: EXPERIMENTAL
Intervention: E-3174 (active metabolite of losartan)
Number of subjects: 0
Study 8471405 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (multiple dosing for 7 days)
Number of subjects: 0
Study 8471405 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 8471405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3861605 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin treatment
Number of subjects: 20
Study 31880758 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS Adsorber therapy
Number of subjects: 32
Study 31880758 — intervention group
Group type: COMPARATOR
Intervention: Sham Adsorber therapy
Number of subjects: 32
Study 30393065 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive behavior in children with no sleep problems at baseline
Number of subjects: 1045
Study 30393065 — intervention group
Group type: EXPERIMENTAL
Intervention: Model performance in the test sample
Number of subjects: 1045
Study 27538531 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 0
Study 24837264 — intervention group
Group type: EXPERIMENTAL
Intervention: OBSERVANT score (risk scoring system based on 7 baseline clinical variables)
Number of subjects: 1256
Study 24837264 — intervention group
Group type: EXPERIMENTAL
Intervention: OBSERVANT score
Number of subjects: 1256
Study 23221159 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial denture
Number of subjects: 53
Study 23221159 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 53
Study 19911431 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-plus consultancy group
Number of subjects: 256
Study 19911431 — intervention group
Group type: COMPARATOR
Intervention: Manual-alone
Number of subjects: 256
Study 18219452 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigonella foenum‐graecum L. total saponins (TFGs)
Number of subjects: 69
Study 18219452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 15730348 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg/day)
Number of subjects: 23
Study 15730348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12600907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0
Study 12600907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10924776 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (MR antagonist), treated for 8 days
Number of subjects: 9
Study 10924776 — intervention group
Group type: COMPARATOR
Intervention: Placebo, treated for 8 days
Number of subjects: 9
Study 8651091 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus urokinase (250 U heparin plus 5,000 U urokinase per minute)
Number of subjects: 280
Study 8651091 — intervention group
Group type: COMPARATOR
Intervention: Heparin (250 U heparin per minute)
Number of subjects: 280
Study 8651091 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus urokinase
Number of subjects: 280
Study 8651091 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 280
Study 1848421 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (3 mg/m2, day 1, 8, 15) plus three cisplatins (35 mg/m2, day 1, 8, 15)
Number of subjects: 61
Study 1848421 — intervention group
Group type: COMPARATOR
Intervention: Vindesine (3 mg/m2, day 1, 8, 15) plus one cisplatin (80 mg/m2, day 1)
Number of subjects: 61
Study 6439057 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 6439057 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 6439057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30354633 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional 1-stent technique
Number of subjects: 529
Study 30354633 — intervention group
Group type: COMPARATOR
Intervention: Planned 2-stent technique
Number of subjects: 529
Study 27556596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonintubated transareolar ETS with a 2-mm needle endoscope
Number of subjects: 168
Study 27556596 — intervention group
Group type: COMPARATOR
Intervention: Intubated transaxillary ETS with a 5-mm thoracoscope
Number of subjects: 168
Study 24633760 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting (EVH)
Number of subjects: 1150
Study 24633760 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvesting (OVH)
Number of subjects: 1150
Study 23180064 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron and dexamethasone
Number of subjects: 0
Study 23180064 — intervention group
Group type: COMPARATOR
Intervention: Granisetron alone
Number of subjects: 0
Study 20211949 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage, irrigation, and fibrinolytic therapy (DRIFT)
Number of subjects: 77
Study 20211949 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (tapping off cerebrospinal fluid)
Number of subjects: 77
Study 20211949 — intervention group
Group type: EXPERIMENTAL
Intervention: DRIFT
Number of subjects: 77
Study 20211949 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 77
Study 19075083 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence program (12 weeks)
Number of subjects: 184
Study 19075083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 184
Study 15760468 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG parameters (RMS and MF) during isometric efforts
Number of subjects: 16
Study 15760468 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=10)
Number of subjects: 16
Study 12359681 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement programs for depression (training experts and nurse specialists, access to nurse specialists for medication follow-up, access to psychotherapists)
Number of subjects: 1356
Study 12359681 — intervention group
Group type: COMPARATOR
Intervention: Usual care for depression
Number of subjects: 1356
Study 10029613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic graciloplasty
Number of subjects: 139
Study 10029613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic gluteoplasty
Number of subjects: 139
Study 7725384 — intervention group
Group type: EXPERIMENTAL
Intervention: EMIT-d.a.u. class (EC) assay
Number of subjects: 6
Study 7725384 — intervention group
Group type: COMPARATOR
Intervention: EMIT-d.a.u. monoclonal amphetamine/methamphetamine (EM) assay
Number of subjects: 6
Study 7725384 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicks inhaler (double dosage)
Number of subjects: 6
Study 7725384 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicks inhaler (recommended dosage)
Number of subjects: 6
Study 1834242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil, 25 micrograms/kg
Number of subjects: 50
Study 1834242 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl, 100 micrograms/kg
Number of subjects: 50
Study 1834242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 50
Study 7032554 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, 120 mg three times a day
Number of subjects: 0
Study 7032554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg three times a day
Number of subjects: 0
Study 30641762 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxycholecalciferol (50000 IU/week)
Number of subjects: 50
Study 30641762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28526471 — intervention group
Group type: EXPERIMENTAL
Intervention: Hockey-stick stylet (Group HS)
Number of subjects: 53
Study 28526471 — intervention group
Group type: EXPERIMENTAL
Intervention: D-blade type stylet (Group DS)
Number of subjects: 53
Study 28526471 — intervention group
Group type: EXPERIMENTAL
Intervention: CoPilot® videolaryngoscope rigid stylet (Group CS)
Number of subjects: 53
Study 28526471 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum elastic bougie (Group GEB)
Number of subjects: 53
Study 28526471 — intervention group
Group type: COMPARATOR
Intervention: No stylet (Group NS)
Number of subjects: 53
Study 25988317 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (5 mg/day)
Number of subjects: 128
Study 25988317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 23146973 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (3 MS criteria)
Number of subjects: 102
Study 23146973 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (5 MS criteria)
Number of subjects: 102